Nixon Peabody LLP advised biotechnology startup Codagenix in securing $1.5M private investment towards the development of its respiratory syncytial virus (RSV) live-attenuated vaccine. The $1.5M was…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
